• Disc Medicine outlined plans to file a complete response to the FDA by end-2026 for bitopertin in EPP.
• FDA Type A meeting alignment that the Phase 3 APOLLO trial could support the CRL response and a traditional approval if positive.
• APOLLO enrollment completed in March 2026 with 183 patients; topline data expected in Q4 2026.
• HELIOS open-label extension showed sustained PPIX reductions beyond 1 year; median exposure 25.3 months with 5% Grade 3 TEAEs.
• RALLY-MF Phase 2 update for selcodebart showed 72% overall response and 56% major response; positioned for about 22,000 anemic MF patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.